The implementation of personalised medicine in childhood cancers has been limited by a lack of clinically validated multi-target sequencing approaches specific for paediatric solid tumours. In order to support innovative clinical trials in high-risk patients with unmet need, we have developed a clinically relevant targeted sequencing panel spanning 311 kb and comprising 78 genes involved in childhood cancers. A total of 132 samples were used for the validation of the panel, including Horizon Discovery cell blends (n=4), cell lines (n=15), formalin-fixed paraffin embedded (FFPE, n=83) and fresh frozen tissue (FF, n=30) patient samples. Cell blends containing known single nucleotide variants (SNVs, n=528) and small insertion-deletions (indels n=108) were used to define panel sensitivities of ≥98% for SNVs and ≥83% for indels [95% CI] and panel specificity of ≥98% [95% CI] for SNVs. FFPE samples performed comparably to FF samples (n=15 paired). Of 95 well-characterised genetic abnormalities in 33 clinical specimens and 13 cell lines (including SNVs, indels, amplifications, rearrangements and chromosome losses), 94 (98.9%) were detected by our approach. We have validated a robust and practical methodology to guide clinical management of children with solid tumours based on their molecular profiles. Our work demonstrates the value of targeted gene sequencing in the development of precision medicine strategies in paediatric oncology.
Introduction
Cancer remains the leading cause of death due to disease in children aged >1 year [1] . Cure rates for paediatric solid tumours have not substantially improved in the past decade with patients having recurrent disease performing particularly badly, reflecting the limitations of current approaches that employ intensive chemotherapy, surgery and radiation [2] [3] [4] . In adults, the stratification of patients by genetic profiling using high throughput sequencing has supported adaptive clinical trials [5, 6] , and there is an urgent need to translate such opportunities to the treatment of childhood disease.
The genomic landscape of paediatric cancer is becoming increasingly well-defined leading to the conclusion that childhood cancers have in general fewer somatic mutations than adults, but that mutations in epigenetic regulators occur at a higher incidence [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] . Key recent findings include recurrent mutations in the genes encoding histones 3.3 and 3.1 (H3F3A and HIST1H3B) as well as the activin A receptor type I (ACVR1) that are unique to paediatric high-grade glioma (pHGG) and diffuse intrinsic pontine glioma (DIPG) [18] [19] [20] . Similarly, ATRX mutations, TERT rearrangements and MYCN amplification define mutually exclusive molecular subgroups of neuroblastoma, all of which are associated with poor prognosis [21] [22] [23] . The newly proposed molecular-based medulloblastoma sub-classification defines subgroups, each of which potentially requires a tailored therapeutic strategy [7, 11, 24] .
Despite our improved knowledge of somatic alterations in paediatric cancers, precision medicine remains unavailable for the majority of patients. For example, a small number of earlyphase paediatric trials are recruiting children whose tumours harbour genetic alterations including ALK genomic alterations (mutations, amplifications or translocations) that can be treated with ALK inhibitors and BRAF V600 mutant tumours that can be treated with BRAF or MEK inhibitors.
In addition, there is now an extensive list of recurrent genetic alterations with potential diagnostic, prognostic or predictive value, and sequential testing of single genes using standard methods has become unfeasible due to lack of available material and high costs. Highthroughput sequencing (also known as next generation sequencing or NGS) offers a solution to these issues. In particular, panel-based NGS assays which simultaneously sequence a targeted set of genes with recurrent alterations, associated with known clinical or biological implications are cheaper, less challenging in terms of interpretation and more suited to clinical diagnostics than current approaches [25] . Despite this, development and validation of high throughput gene panel sequencing is challenging. Typically, DNA is only available from formalin-fixed, paraffinembedded (FFPE) samples, which yields relatively poor quality DNA. DNA extraction and library construction to clinical laboratory standards requires optimisation, and it is necessary to construct a standardised informatics pipeline that identifies and interprets actionable mutations.
Appropriate and rapid clinical reporting of identified variants and incorporation of the results into the electronic patient records also need to be considered if molecular stratification of childhood cancer is to be successfully translated to the clinic [26] . There are several examples of validation and implementation of targeted sequencing in adult cancer [27] [28] [29] [30] . In the past two years, several approaches using high-throughput sequencing have been applied for clinical decision-making in children with solid tumours [31] [32] [33] [34] , however a clinically validated panel specifically targeting recurrent alterations in childhood cancers using archival FFPE specimens would significantly assist the development of molecular stratification strategies in paediatric oncology.
Here we describe the development and validation, within an accredited clinical pathology laboratory (CPA UK), of a paediatric solid tumour sequencing panel for use with either routine FFPE or fresh frozen (FF) samples. As part of the validation, we established overall performance, sensitivity, specificity, repeatability, reproducibility, accuracy and limit of detection, following guidelines previously described for validation of genetic tests [35] .
Results

Selection of Panel Content
The panel design covers a total of 78 genes (Table 1) , either recurrently altered in paediatric cancers or clinically actionable in adult cancers and with potential application in childhood tumours. The genes were selected in wide-collaboration with national experts in paediatric oncology patient care covering all areas of paediatric solid tumours (glioma, medulloblastoma, bone sarcomas, soft tissue sarcomas, renal tumours and neuroblastoma among others).
Targets were chosen by consensus based on most clinically relevant aberrations. Factors
influencing the choice of targets included: childhood tumour type where alterations have been reported, molecules targeting these genes and clinical trials available for children with solid tumours ( Supplemental Table S1 A). A library of customized biotinylated DNA probes was designed to capture a total of ~311(kilobase) kb for the detection of single nucleotide variants (SNVs), short insertion-deletions (indels), copy number variations and structural rearrangements (Supplemental Table S1 B). Exons were padded with 5 base pairs (bp) of intronic sequence to increase exon depth and for detection of splice-site variants.
Panel Validation
Research use of sequence capture assays has become common, but basing clinical care on gene panel sequencing results requires confident calling of both variant and non-variant sequence, and a full understanding of the performance of the assay. Implementation in the clinic therefore requires robust validation in an accredited laboratory.
To validate the paediatric gene panel, we followed the standardised framework for clinical assay validation set out by Mattocks et al. [35] . We determined overall performance of the panel across the target regions, measuring precision, sensitivity and specificity. As a standard, we used a set of four Horizon cell blends previously characterized by NGS and droplet digital PCR (ddPCR) ( Supplemental Table S2 A and S2 B) and 15 paediatric cell lines with known variants.
For further validation, we performed capture and sequencing on 83 FFPE and 30 FF clinical samples ( Supplemental Table S3 ).
Overall Performance
Overall, the panel performed well, with over 96% of 901 regions of interest achieving specification. Only 24 (2.7%) regions were classified as underperforming across the four cell blends and five FFPE samples, with read depth lower than 2 x standard deviation (SD) of the mean based on log 2 (Supplemental Tables S4 A and S4 B). 22 of 24 underperforming regions were located within highly GC-enriched regions, which are known to be refractory to efficient hybridization and/or amplification ( Figure 1 and Supplemental Table S4 C) .
Quality and coverage metrics were generated across all samples ( Supplemental Table S5 and S6). The average total number of reads was 8.8x10 6 
Limit of detection
To determine the limit of detection, SNVs present in the cell blends at known variant allele frequency (VAF) were used. The pipeline detected all 61 SNVs including 33 SNVs with an expected VAF of 4-5%. 15/17 expected indels were detected. Of the two indels not detected, one was 18 bp in length at an expected VAF of 4.2%, whilst the other was 2 bp at 5% VAF ( Figure 2 and Supplemental Table S7 A). We therefore established a minimum threshold of 5% VAF in the analysis pipeline, which allows for detection of a heterozygous mutation when >10% neoplastic cells are present in the tumour sample.
Assessment of Precision
To measure precision, we took advantage of natural variants present as intrinsic "background" SNVs and indels in the captured regions from the four cell blends. Precision was assessed by comparing the alterations expected with those detected to obtain within run-precision (repeatability), and between run-precision data (intermediate precision). Variants ≤ 5% in all four blends and within poor performing regions were excluded leaving a total of 528 SNVs (132 variants in 4 blends) and 108 indels (27 indels in 4 blends) for analysis. All of the 528 SNVs and 90 out of 108 (83%) indels were detected (Supplemental Table S8 ). Figure S3 and Supplemental Figure S4 
Repeatability
Assessment of sensitivity and specificity
To determine sensitivity we used the same background 528 SNVs and 108 indels, together with the known cancer-specific variants (61 SNVs and 17 indels) from the four cell blends. SNVs and indels were called and their presence was compared to the list of variants expected in the capture regions from the cell blends ( Supplemental Table S7 A and Supplemental Table S8 ). All To determine specificity, we used the cancer-specific data from the four cell blends harbouring a total of 61 true positive and 87 true negative SNVs ( Supplemental Table S7B ). There were insufficient true negatives (n=3) to determine specificity for indels. SNVs were called and their presence was compared to the list of variants expected in the capture regions from the cell blends. The specificity of cancer-specific SNVs was ≥98% [95%CI:0.946-1]. Positive-Predictive Value (PPV) was ≥98% [95%CI:0.926-1] and the Negative-Predictive Value (NPV) was ≥98%
The range of VAF for the SNVs detected by our pipeline, including the background and the cancer specific variants (528 + 61 = 589), was 23% at ≥ 50% VAF (134/589), 35% at 50-20% of VAF (207/589) and 42% at < 20% (248/589). The range of VAF for the indels detected by our pipeline including the background and cancer specific indels (90 + 15 = 105) was 0% at > 50% of VAF (0/105), 31% at 50-20% of VAF (33/105) and 69% <20% (72/105).
Performance and Variant Detection comparison in paired FF-FFPE clinical samples
To assess the performance of the panel on real clinical material we compared 15 paired clinical DNA samples isolated from both FF and FFPE samples. For the FFPE samples, we obtained an average of 93.4% ± 5.42% and 80.3% ± 20.3% of targeted positions covered at depths of ≥ 100x and ≥ 250x respectively. The overall mean depth for FFPE was 785 ± 333. Overall percentage of bases from unique reads on target for FFPE was 47.6% ± 2.3%. For FF samples, we obtained an average of 96.6% ± 0.6% and 90.9% ± 1.9% of targeted positions covered at depths of ≥ 100x and ≥ 250x respectively. The overall mean depth for FF was 977 ± 142.
Overall percentage of bases from unique reads on target for FF was 44% ± 2.2%. As expected, duplicates were substantially lower in FF samples (54.5% for FFPE vs 29.9% for FF). Insert size for the library pre-capture DNA was 285 bp ± 24 for FFPE and 326 bp ± 24 for FF (Table 4 ).
VAFs found in the paired FF-FFPE samples were compared, obtaining an overall correlation of r 2 = 0.983 (95%CI: 0.984-0.985; p<0.0001) ( Figure 3 and Supplemental Figure S5 ). A total of 42.3% (5562/13146) variants were detected in FF but not in FFPE, of which 78.1% (4346/5562) had VAF below 5%, with 17.6% (982/5562) having VAF between 5-10%. Less than 5% variants missed in FFPE samples were present in FF at VAF above 10%.
Conversely, a total of 8.2% (1084/13146) variants were detected in FFPE but not in FF, of which 50.8% (551/1084) had VAF below 5%, with 33.2% (360/1084) having VAF between 5-10%, and the remaining 16.0% (173/1084) were present in FFPE only at VAF above 10%. (Tables 5 and 6 and Supplemental Table S9 ).
Detection of known variants in paediatric samples
Detection of Rearrangements
Five sarcoma FFPE samples were included in the analysis where translocations had previously been detected by RT-qPCR involving EWSR1. Rearrangements in EWSR1 were detected in four out of the five FFPE samples (80%) leading to fusion genes of EWSR1 with partners ATF1 (detected in two samples), FLI1 and CREB1 (Supplemental Figure S6 ). The fusion not detected was EWSR1-NR4A3. This is too small a sample to confirm validation of the panel for detection of translocations at this stage and further work is in progress.
DISCUSSION
Targeted therapies are already the standard of care for several molecular subgroups of adult cancers. EGFR mutations or ALK rearrangements in lung cancer, BRAF V600E mutations in metastatic melanoma and breast cancer patients harbouring HER2 amplifications are examples of therapeutic biomarkers routinely used in the adult population [36] [37] [38] . The implementation of personalised medicine in paediatric oncology has remained challenging partly due to the low incidence of childhood cancer, accessibility of drugs and regulatory hurdles [39] . Nevertheless, the understanding of genetics in childhood cancer over the last decade has improved thanks to large sequencing initiatives across the world [31] [32] [33] . The updated World Health Organization Classification (WHO) classification of brain tumours based on molecular features is a clear example of the huge impact of applying molecular profiling to guide diagnosis and treatment with the potential to improve outcomes in childhood cancers [40] .
We have developed an NGS targeted sequencing based diagnostic test to accurately detect clinically relevant genomic alterations across 78 cancer genes in routine FFPE as well as FF paediatric samples. The overall performance of our assay was excellent; from the 901 regions captured only 24 (<3%) failed the quality control metrics mainly as a result of being located in GC-rich regions, and should be noted for future panel design. VAF for known SNVs and indels were very similar in within-run and between-run replicates, demonstrating that the assay is repeatable and reproducible. SNVs were detected at a wide range of VAFs simulating the heterogeneity expected in cancer samples including 33 SNVs with an expected VAF of 4-5%.
The detection of variants at low VAF is crucial, especially in samples with a low neoplastic cell content. Sensitivity was ≥98% for SNVs and ≥83% for indels and specificity ≥98% for SNVs.
False-negative calls were mostly at low VAF (≤5%) and predominantly occurred at splice sites.
Variants were analysed in exons and the surrounding 5 bp, but were not called by our pipeline if they occurred in the last base. This could be solved expanding the sequence covered by bed file at intron:exon boundaries, but the relevance of these variants remains unclear. There is currently no consensus as to the most appropriate minimum region of interest to cover at splice sites for clinical reporting and in many cases the biological meaning of these mutations are unknown. The latest guidelines recommend calling likely disrupted gene function in nonsense, frameshift, canonical ±1 or ±2 splice sites, initiation codon, and single exon or multi-exon deletion, all of which would be covered with our current pipeline [41] .
We also compared the performance of paired FFPE-FF specimens obtaining comparable quality metrics between both tissue types, as well as a high overall correlation of VAF. This is particularly important as most clinical samples routinely available are derived from FFPE tissue where nucleic acid quality is generally compromised and chemically challenged, leading to DNA degradation and potential deamination or oxidation artefacts. The discrepancies of the variants observed between FFPE and FF were mainly at low VAF, below or at the lower limit of detection of our approach. The discrepancies of the variants above 10% could be explained by variation in neoplastic cell content between FF and FFPE and intra-tumour heterogeneity leading to subclonal alterations. Three of the samples with more striking differences were brain tumours which are well known as highly heterogeneous tumours [42, 43] .
We verified the accuracy of our NGS approach in cell lines and clinical specimens (FFPE and FF) containing known genetic abnormalities previously characterized by other methodologies and obtained a high concordance (r 2 = 0.983). The FFPE and FF samples used for the validation were a cohort of specimens from several hospitals across the world. We obtained reproducible and accurate results from different quality samples processed in different pathology laboratories, demonstrating the value of this approach for the development of national and international clinical trials in paediatric oncology.
Our data shows that this NGS approach can detect structural variants, including amplifications, deletions and chromosomal rearrangements. These types of variants are not generally detected with commercial amplicon-based NGS panels, despite being of critical importance for the clinical management and diagnosis of paediatric patients (e.g. MYCN amplification in neuroblastoma, EWSR1 in Ewing's sarcoma). Only one out of five chromosomal rearrangements involving EWSR1 was not identified by the assay which could be due to the lack of coverage at the intronic genomic location of the breakpoint. As expected, this is one of the limitations of the methodology, as capturing intronic regions commonly involved in translocations poses challenges associated to the presence of repetitive sequence elements. This can be partially overcome by including capture baits for the breakpoint regions of the most common partner genes involved in the translocations.
In summary, we have developed a robust clinical test that can detect SNVs, small indels, copy number variation and with high reproducibility and repeatability in routine clinical FFPE samples from a variety of centres. Our approach has been incorporated into a pilot molecular profiling study for paediatric patients at the Royal Marsden Hospital (London, UK) and this has now been extended across the UK as the METEOR programme, an interim step towards the UK's more Table S3 ).
Local institutional review board approval was obtained for the project in addition to separate approvals from the contributing tumour banks (The Children's Cancer and Leukaemia Group Tumour Bank and the Queensland Children's Tumour Bank).
Sample preparation
Assessment from haematoxylin and eosin (H&E) stained slides was performed by experienced pathologists to mark the region of the section containing tumour and to estimate neoplastic cell content, defined as the percentage of neoplastic cells out of total nucleated cells in the marked area. Tumour cellularity, reflecting the density of tumour nuclei, was also estimated. Macrodissection of the marked area was performed, when appropriate, to enrich the tumour content.
DNA from blood and cell lines, FF and FFPE samples was extracted using the QIAamp DNA blood mini kit, the QIAamp DNA mini kit and the QIAamp DNA FFPE tissue kit (Qiagen, Hilden, Germany), respectively. For specimens where DNA was extracted at local centres, methods are provided in supplementary methods. DNA was quantified using Qubit dsDNA High Sensitivity Assay Kit with the Qubit 2.0 fluorometer, (Invitrogen, Carlsbad, CA). Analysis by TapeStation 2200 using the genomic DNA ScreenTape assay (Agilent Technologies, Santa Clara, CA) was performed to determine the degree of fragmentation of genomic DNA prior to library preparation.
Based on optimization studies, samples yielding DNA with median fragment length > 1000 bp were processed using 200 ng DNA. Samples with DNA < 1000 bp were processed using 400 ng if there was sufficient DNA. 
Gene Panel Capture and Sequencing
Cell blends
The four cell blends contained 163 SNVs and 34 indels common to all four blends (background variants) ( Supplemental Table S2A ). Additionally, there were 61 SNVs and 17 indels, cancer variants, which were unique between blends, introduced at known VAF, and verified by ddPCR (Supplemental Table S2B ). The four cell blends were used to assess overall performance, repeatability, intermediate precision, sensitivity and limit of detection. Specificity was determined using 87 true negative SNV sites (wild type) where another blend harboured a mutation at the corresponding position. The cell blends were processed and sequenced in two different runs by two independent users. 
Overall Performance
Limit of detection
To assess the limit of detection and determine a reliable cut off for the analysis we used the unique cancer-specific set of variants from the four cell blends introduced at range of VAFs from 4% to 30%, defined by ddPCR.
Precision
Repeatability (or within-run precision) was determined by comparing the cell blend background variant data across the 4 different samples in the same run for variant detection and VAF. Intrarun pairwise correlation was calculated for two runs where the cell blends were prepared and sequenced by different users generating two sets of repeatability data.
Intermediate precision (or between-run precision) was determined by comparing the cell blend background variant data between two runs for variant detection and VAF. Between-run pairwise correlation was calculated from two different runs prepared by different users and sequenced on different MiSeq instruments.
Sensitivity and specificity
The sensitivity of the panel was determined by separately comparing the cell blend background variants and the cancer-specific variants introduced at known VAF. Specificity was determined using the cell blend cancer-specific set of data with known variants and known true negative sites. Variants were classified according to the different ranges of frequencies of the variants present in the DNA blends. We also determined Positive-Predictive Value and Negative-Predictive Value. 13 paediatric cancer cell lines were tested harbouring a total of 30 known SNVs, deletions and amplifications previously identified by the Cancer Cell Line Encyclopaedia using Target Enrichment Sequencing (Agilent Technologies, Santa Clara, CA) and other published data [45] [46] [47] [48] [49] [50] . Furthermore 33 samples (FF=14, FFPE=19) had a total of 65 known genetic alterations including i) SNVs detected by Sanger Sequencing (H3F3A, TP53, CTNNB1, HIST1H3B , ALK, and iii) rearrangements by Real-Time Quantitative PCR involving ESWR1 as previously described [55, 56] (Refer to Supplemental Methods). We are enormously grateful to the Christopher's Smile charity (grant numbers CSM 002 and CSM 003) for their support and enthusiasm to provide children with more effective and less toxic targeted drugs through molecular profiling. We also thank the contribution of Children's Cancer and Leukaemia Group (CCLG).
Correlation between NGS targeted panel and other methodologies
Fresh frozen vs FFPE samples
Conflicts of interest
The authors declared no conflict of interest with the submitted paper. formalin-fixed paraffin embedded (x axis) and fresh frozen (y axis) paired samples. Supplemental Table S1 . and wild type sties used to determine specificity (n=87) on the four HD cell blends. Supplemental Table S3 . List of all samples used, including: tumour content, cellularity, tumour type and known genetic alterations. Supplemental Table S4 . Percentage of GC content in each he targeted region. Supplemental Table S5 . Quality Control metrics for the 132 samples used. Supplemental Table S6 . Coverage metrics for the 132 samples used. Supplemental Table S8 . Variant allele frequency observed on the HD cell blends for the selected single nucleotide variants (SNV, n=132) and insertion deletions (indels, n=27) used for the assessment of precision, sensitivity and specificity. Supplemental Table S9 . 
Financial Support
Supplementary Tables
